---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-056160"
form_type: "8-K"
ticker: "SGMT"
cik: "0001400118"
company_name: "Sagimet Biosciences Inc."
filed_at: "2025-06-04T23:59:59+00:00"
generated_at: "2026-05-19T23:44:56.474735+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Sagimet partner Ascletis reports positive Phase 3 acne results for denifanstat; Sagimet starts Phase 1 of TVB-3567

## Summary
- Denifanstat (50mg once daily) met all primary and secondary endpoints vs placebo in Phase 3 acne trial (n=480) in China.
- Treatment success (IGA) 33.2% denifanstat vs 14.6% placebo (p<0.0001); total lesion count change −57.4% vs −35.4%.
- Denifanstat well-tolerated; TEAEs comparable to placebo, only dry skin (6.3%) and dry eye (5.9%) above 5%.
- Ascletis plans to submit denifanstat for approval to China's NMPA; Sagimet initiated Phase 1 of TVB-3567 for US acne.
- Oral FASN inhibition offers novel mechanism for moderate-to-severe acne, a condition affecting 640M+ globally.

## SEC filing metadata
- accession: 0001104659-25-056160
- form_type: 8-K
- ticker: SGMT
- cik: 0001400118
- company_name: Sagimet Biosciences Inc.
- filed_at: 2025-06-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1400118/000110465925056160/0001104659-25-056160-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1400118/000110465925056160/tm2517101d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-056160
- JSON: https://secwatch.observer/filing/0001104659-25-056160.json
- Plain text: https://secwatch.observer/filing/0001104659-25-056160.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.